Tazemetostat
Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers.
Accelerated approvals in 2020 (epithelioid sarcoma; relapsed EZH2-mutant or option-less FL). Modest response rates (15% and ~35-69%) with good tolerability; SYMPHONY-1 combined it with lenalidomide-rituximab. Withdrawn worldwide in March 2026 over secondary haematologic malignancies (T-ALL, MDS), ending the EZH2 class in lymphoma for now.
- 23 Jan 2020ApprovalUS
Accelerated approval, epithelioid sarcoma
- 18 Jun 2020ApprovalUS
Accelerated approval, follicular lymphoma
- Mar 2026WithdrawalGlobal
Withdrawn over secondary haematologic malignancies
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2020 | Epithelioid sarcoma; relapsed FL (EZH2-mutant after 2 lines; wild-type without alternatives) — Withdrawn March 2026 |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Tazemetostat" OR ABSTRACT:"Tazemetostat" OR TITLE:"Tazverik" OR ABSTRACT:"Tazverik") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tazemetostat, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductUmbralisib
Shares Indication withdrawal, Follicular lymphoma and the tag gap-fill.
- ProductCopanlisib
Shares Indication withdrawal, Follicular lymphoma and the tag gap-fill.
- ProductIdelalisib
Shares Indication withdrawal, Follicular lymphoma and the tag gap-fill.
- ProductDuvelisib
Shares Indication withdrawal and the tag gap-fill.
- ProductPanobinostat
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag gap-fill.
- ProductBelinostat
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag gap-fill.
- ProductRomidepsin
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag gap-fill.
- TargetCSF1R
Shares Cold tumours: immune deserts and exclusion, Sarcomas (soft tissue, bone, GIST) and the tag gap-fill.